ArticleJournal of neuro-oncology2019
Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment.
Adela Wu et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
90 papers cite itlatest 60 shown
this papercites it